



NEWS RELEASE

FOR IMMEDIATE RELEASE

CONTACT:

Michele Rozen, Pure Communications
617-953-2214

Catabasis Pharmaceuticals Named One of the “Fierce 15” Leading Biotech Companies of 2010

CAMBRIDGE, Mass. – September 15, 2010 – [Catabasis Pharmaceuticals](#), a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced today that FierceBiotech has named Catabasis as one of 2010’s “Fierce 15,” designating it as one of the most promising biotech companies in the industry.

“Catabasis has everything going for it that a biotech start-up needs and wants: An experienced team of successful developers at the helm, a prominent scientific founder who’s well known in the disease field they’re targeting and a hefty, \$39.6 million first-round from A-list investors to put the whole program together in style,” said John Carroll, editor of FierceBiotech. “It’s very much early days for Catabasis, which landed its Series A just last April. But the biotech startup is moving fast to enter the clinic with a new therapy based on a program that’s already achieved critical proof-of-concept data in a human study. And more will follow.”

Every year, FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position. A complete list of “Fierce 15” companies is available online at www.fiercebiotech.com.

“We are very pleased to be recognized in FierceBiotech’s 8th annual ‘Fierce 15’ list,” said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis Pharmaceuticals. “Millions of Americans are affected by type 2 diabetes, and there remains a significant unmet need for the treatment of the inflammatory component of the disease. We are excited about the data generated to date for CAT1000, which represents a potential breakthrough approach in targeting diabetes. Our novel, proprietary SMART-linker technology platform will continue to be Catabasis’ engine for bringing forward high-value product candidates to treat inflammatory and metabolic diseases, and we will continue growing our company in support of that goal.”

About Catabasis

Catabasis is dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. Using its proprietary Catabasis SMART-linker technology, Catabasis has developed a pipeline of molecules that amplify the beneficial effects of salicylates and omega-3 fatty acids to target the underlying etiologies of a spectrum of complex human diseases. The Catabasis approach dramatically enhances the therapeutic potential of DHA and EPA, two essential fatty acids found in fish oil, by improving the delivery, potency and efficacy. Catabasis was founded in 2008 and is headquartered in Cambridge,

Mass. More information on the company can be found on its website at www.catabasispharma.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at <http://www.fiercebiotech.com>.

###